{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:55:30Z","timestamp":1778561730068,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1002\/jps.23611","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:25:07Z","timestamp":1369095907000},"page":"3205-3219","source":"Crossref","is-referenced-by-count":30,"title":["Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation"],"prefix":"10.1016","volume":"102","author":[{"given":"Christian","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstin","family":"Thelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu","family":"Selen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1002\/jps.23611_bb0005","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00003088-200847100-00003","article-title":"Towards quantitative prediction of oral drug absorption","volume":"47","author":"Dressman","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1002\/jps.23611_bb0010","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1002\/jps.23611_bb0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0090-9556(24)15229-4","article-title":"Characterization of human small intestinal cytochromes P-450","volume":"27","author":"Zhang","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1002\/jps.23611_bb0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0090-9556(25)08440-5","article-title":"Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test","volume":"22","author":"Lown","year":"1994","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1002\/jps.23611_bb0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-199426020-00002","article-title":"Grapefruit juice and drugs. How significant is the interaction?","volume":"26","author":"Bailey","year":"1994","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1002\/jps.23611_bb0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2125.1998.00764.x","article-title":"Grapefruit juice-drug interactions","volume":"46","author":"Bailey","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"8736","key":"10.1002\/jps.23611_bb0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(91)90872-M","article-title":"Interaction of citrus juices with felodipine and nifedipine","volume":"337","author":"Bailey","year":"1991","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/jps.23611_bb0040","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/75.9.933","article-title":"Drug-grapefruit juice interactions","volume":"75","author":"Kane","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1002\/jps.23611_bb0045","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1172\/JCI119439","article-title":"Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression","volume":"99","author":"Lown","year":"1997","journal-title":"J Clin Invest"},{"issue":"1-2","key":"10.1002\/jps.23611_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00192360","article-title":"Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects","volume":"49","author":"Lundahl","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jps.23611_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2710.2004.00618.x","article-title":"Grapefruit juice-nifedipine interaction: Possible involvement of several mechanisms","volume":"30","author":"Odou","year":"2005","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1002\/jps.23611_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1995.tb04534.x","article-title":"Factors affecting the absolute bioavailability of nifedipine","volume":"40","author":"Rashid","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1002\/jps.23611_bb0065","first-page":"1228","article-title":"Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins","volume":"25","author":"Schmiedlin-Ren","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1002\/jps.23611_bb0070","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjhyper.2005.11.003","article-title":"Interaction of grapefruit juice and calcium channel blockers","volume":"19","author":"Sica","year":"2006","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1002\/jps.23611_bb0075","first-page":"522","article-title":"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation","volume":"49","author":"Sigusch","year":"1994","journal-title":"Pharmazie"},{"issue":"4","key":"10.1002\/jps.23611_bb0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s002280050296","article-title":"The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice","volume":"52","author":"Clifford","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1002\/jps.23611_bb0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0009-9236(97)90189-2","article-title":"Drug interactions with grapefruit: Whose responsibility is it to warn the public?","volume":"61","author":"Spence","year":"1997","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jps.23611_bb0090","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1002\/jps.23611_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0009-9236(95)90188-4","article-title":"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice","volume":"58","author":"Hukkinen","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1002\/jps.23611_bb0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0009-9236(95)90032-2","article-title":"Disposition of intravenous and oral cyclosporine after administration with grapefruit juice","volume":"57","author":"Ducharme","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"8955","key":"10.1002\/jps.23611_bb0105","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(95)90700-9","article-title":"Effect of grapefruit juice on blood cyclosporin concentration","volume":"345","author":"Yee","year":"1995","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/jps.23611_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/cp.1999.v66.100453001","article-title":"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin","volume":"66","author":"Lilja","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"no 235","key":"10.1002\/jps.23611_bb0115","first-page":"5","article-title":"Grapefruit juice and saquinavir","author":"James","year":"1995","journal-title":"AIDS Treat News"},{"issue":"3","key":"10.1002\/jps.23611_bb0120","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0022-3565(25)11138-5","article-title":"Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice","volume":"261","author":"Miniscalco","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1002\/jps.23611_bb0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajcn\/83.5.1097","article-title":"A furanocoumarin-free grapefruit juice establishes fura-nocoumarins as the mediators of the grapefruit juice-felodipine interaction","volume":"83","author":"Paine","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1002\/jps.23611_bb0130","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0169-409X(02)00013-3","article-title":"Physiologically based pharmacokinetic simulation modelling","volume":"54","author":"Grass","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1002\/jps.23611_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2010.10.012","article-title":"Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles","volume":"77","author":"Juenemann","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"10.1002\/jps.23611_bb0140","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cbdv.200900054","article-title":"Measurement and prediction of oral absorption","volume":"6","author":"Keldenich","year":"2009","journal-title":"Chem Biodivers"},{"issue":"4","key":"10.1002\/jps.23611_bb0145","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1208\/s12248-008-9061-4","article-title":"Understanding the effect of API properties on bioavailability through absorption modeling","volume":"10","author":"Kesisoglou","year":"2008","journal-title":"AAPS J"},{"issue":"1","key":"10.1002\/jps.23611_bb0150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejps.2005.08.011","article-title":"A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study","volume":"27","author":"Kuentz","year":"2006","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1002\/jps.23611_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejpb.2008.10.019","article-title":"Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products","volume":"72","author":"Okumu","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"issue":"1-2","key":"10.1002\/jps.23611_bb0160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0928-0987(02)00132-X","article-title":"Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA","volume":"17","author":"Parrott","year":"2002","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1002\/jps.23611_bb0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1208\/s12248-008-9079-7","article-title":"Predicting pharmacokinetics of drugs using physiologically based modeling\u2014Application to food effects","volume":"11","author":"Parrott","year":"2009","journal-title":"AAPS J"},{"issue":"1","key":"10.1002\/jps.23611_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2009.05.009","article-title":"Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling","volume":"73","author":"Shono","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"10.1002\/jps.23611_bb0175","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/jps.22026","article-title":"Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing","volume":"99","author":"Thelen","year":"2010","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1002\/jps.23611_bb0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejpb.2012.05.008","article-title":"Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model","volume":"82","author":"Wagner","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"10.1002\/jps.23611_bb0185","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1211\/jpp.61.07.0008","article-title":"Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: Inter-individual variability of cimetidine absorption","volume":"61","author":"Willmann","year":"2009","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1002\/jps.23611_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2010.06.003","article-title":"Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs","volume":"76","author":"Willmann","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1002\/jps.23611_bb0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1208\/s12248-010-9250-9","article-title":"Utility of physiologically based absorption modeling in implementing quality by design in drug development","volume":"13","author":"Zhang","year":"2011","journal-title":"AAPS J"},{"issue":"4","key":"10.1002\/jps.23611_bb0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/j.1552-4604.1983.tb02720.x","article-title":"Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects","volume":"23","author":"Foster","year":"1983","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1002\/jps.23611_bb0205","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1620\/tjem.148.421","article-title":"Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients","volume":"148","author":"Imai","year":"1986","journal-title":"Tohoku J Exp Med"},{"issue":"22","key":"10.1002\/jps.23611_bb0210","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/0006-2952(84)90165-5","article-title":"Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man","volume":"33","author":"Kleinbloesem","year":"1984","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1002\/jps.23611_bb0215","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/clpt.1984.105","article-title":"Nifedipine: Kinetics and dynamics in healthy subjects","volume":"35","author":"Kleinbloesem","year":"1984","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1002\/jps.23611_bb0220","first-page":"S340","article-title":"Clinical pharmacokinetics of calcium channel antagonists","volume":"4","author":"McAllister","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"10.1002\/jps.23611_bb0225","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2125.1988.tb05256.x","article-title":"The pharmacokinetics of oral nifedipine\u2014A population study","volume":"25","author":"Renwick","year":"1988","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1002\/jps.23611_bb0230","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2125.1988.tb03307.x","article-title":"Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine","volume":"25","author":"Robertson","year":"1988","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1002\/jps.23611_bb0235","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2125.1984.tb02569.x","article-title":"The first pass metabolism of nifedipine in man","volume":"18","author":"Waller","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.23611_bb0240","unstructured":"German prescribers information. Accessed November, 2012, at: www.fachinfo.de."},{"issue":"3","key":"10.1002\/jps.23611_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s002280050092","article-title":"Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine","volume":"50","author":"Bode","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"1-2","key":"10.1002\/jps.23611_bb0250","first-page":"13","article-title":"Clinical pharmacokinetics of calcium ion antagonists","volume":"3","author":"Eichelbaum","year":"1980","journal-title":"Clin Invest Med"},{"issue":"4 Pt 2","key":"10.1002\/jps.23611_bb0255","first-page":"II18","article-title":"Pharmacokinetics and metabolism of nifedipine","volume":"5","author":"Raemsch","year":"1983","journal-title":"Hypertension"},{"issue":"2","key":"10.1002\/jps.23611_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00003495-198325020-00002","article-title":"Calcium antagonists. Pharmacokinetic properties","volume":"25","author":"Kates","year":"1983","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/jps.23611_bb0265","first-page":"63","article-title":"Pharmacokinetics of nifedipine","volume":"5","author":"Pasanisi","year":"1985","journal-title":"Int J Clin Pharmacol Res"},{"issue":"1","key":"10.1002\/jps.23611_bb0270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1987.110","article-title":"Effect of food on nifedipine pharmacokinetics","volume":"42","author":"Reitberg","year":"1987","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1002\/jps.23611_bb0275","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"7","key":"10.1002\/jps.23611_bb0280","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm Res"},{"issue":"3","key":"10.1002\/jps.23611_bb0285","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2005.03.002","article-title":"Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds","volume":"60","author":"Vertzoni","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1002\/jps.23611_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.20212","article-title":"Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid\/base titrations and calculated solubilities","volume":"94","author":"Glomme","year":"2005","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1002\/jps.23611_bb0295","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1208\/s12249-008-9161-6","article-title":"A standardized mini paddle apparatus as an alternative to the standard paddle","volume":"9","author":"Klein","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1002\/jps.23611_bb0300","series-title":"The United States Pharmacopeia 31","author":"The United States Pharmacopeial Convention","year":"2008"},{"issue":"12","key":"10.1002\/jps.23611_bb0305","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1002\/jps.22726","article-title":"Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: Oral solutions","volume":"100","author":"Thelen","year":"2011","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1002\/jps.23611_bb0310","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/jps.22825","article-title":"Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms","volume":"101","author":"Thelen","year":"2012","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1002\/jps.23611_bb0315","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/17425255.1.1.159","article-title":"From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools","volume":"1","author":"Willmann","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1002\/jps.23611_bb0320","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1023\/B:PHAM.0000003373.72652.c0","article-title":"A physiologic model for simulating gastrointestinal flow and drug absorption in rats","volume":"20","author":"Willmann","year":"2003","journal-title":"Pharm Res"},{"issue":"16","key":"10.1002\/jps.23611_bb0325","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1021\/jm030999b","article-title":"A physiological model for the estimation of the fraction dose absorbed in humans","volume":"47","author":"Willmann","year":"2004","journal-title":"J Med Chem"},{"issue":"3-4","key":"10.1002\/jps.23611_bb0330","first-page":"5","article-title":"Basic anatomical and physiological data for use in radiological protection: Reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals 2002. ICRP Publication 89","volume":"32","author":"Valentin","year":"2002","journal-title":"Ann ICRP"},{"issue":"3","key":"10.1002\/jps.23611_bb0335","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","article-title":"Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs","volume":"34","author":"Willmann","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"10.1002\/jps.23611_bb0340","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","article-title":"PK-Sim(R): A physiologically based pharmacokinetic \u201cwhole-body\u201d model","volume":"1","author":"Willmann","year":"2003","journal-title":"Biosilico"},{"issue":"6","key":"10.1002\/jps.23611_bb0345","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199222060-00002","article-title":"Clinical pharmacokinetics of calcium antagonists","volume":"22","author":"Kelly","year":"1992","journal-title":"An update. Clin Pharmacokinet"},{"issue":"1","key":"10.1002\/jps.23611_bb0350","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2165\/00003088-198712010-00002","article-title":"Nifedipine. Relationship between pharmacokinetics and pharmacodynamics","volume":"12","author":"Kleinbloesem","year":"1987","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1002\/jps.23611_bb0355","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1002\/jps.23611_bb0360","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1124\/jpet.106.106013","article-title":"Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism","volume":"318","author":"Galetin","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1002\/jps.23611_bb0365","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.23611_bb0370","first-page":"1","article-title":"Studies on the gastric emptying mechanism in healthy persons and patients after partial gastrectomy","volume":"404","author":"Berger","year":"1969","journal-title":"Acta Chir Scand Suppl"},{"issue":"8","key":"10.1002\/jps.23611_bb0375","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gut.12.8.611","article-title":"An evaluation of indium DTPA chelate in the measurement of gastric emptying by scintiscanning","volume":"12","author":"Heading","year":"1971","journal-title":"Gut"},{"issue":"6","key":"10.1002\/jps.23611_bb0380","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2125.1986.tb02954.x","article-title":"The relationship between gastric emptying of semisolids and paracetamol absorption","volume":"22","author":"Petring","year":"1986","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1002\/jps.23611_bb0385","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.1990.tb03691.x","article-title":"Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption","volume":"29","author":"Petring","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1002\/jps.23611_bb0390","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1023\/A:1012160419520","article-title":"Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence","volume":"14","author":"Marston","year":"1997","journal-title":"Pharm Res"},{"issue":"5","key":"10.1002\/jps.23611_bb0395","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2125.1986.tb02936.x","article-title":"The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine","volume":"22","author":"Challenor","year":"1986","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jps.23611_bb0400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(24)01402-9","article-title":"Is the role of the small intestine in first-pass metabolism overemphasized?","volume":"51","author":"Lin","year":"1999","journal-title":"Pharmacol Rev"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915309540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915309540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T10:42:45Z","timestamp":1746009765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915309540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0022354915309540"],"URL":"https:\/\/doi.org\/10.1002\/jps.23611","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}